OPTOMED — Optomed Oyj Income Statement
0.000.00%
Last trade - 00:00
- €95.61m
- €87.63m
- €15.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15 | 13 | 14.8 | 14.7 | 15.1 |
Cost of Revenue | |||||
Gross Profit | 9.69 | 8.8 | 9.75 | 9.21 | 10.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17.6 | 15.9 | 19.6 | 19.8 | 19.1 |
Operating Profit | -2.6 | -2.91 | -4.78 | -5.1 | -3.97 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.95 | -3.25 | -4.33 | -5.55 | -4.52 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.88 | -3.18 | -4.25 | -5.47 | -4.44 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.88 | -3.18 | -4.25 | -5.47 | -4.44 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.88 | -3.18 | -4.25 | -5.47 | -4.44 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.205 | -0.232 | -0.288 | -0.328 | -0.265 |
Dividends per Share |